Background
==========

For decades, hyperglycemia has been a frequent yet intractable issue in patients who are admitted to the intensive care unit (ICU), and hyperglycemia is associated with severe adverse reactions including high susceptibility to infectious complications, oxidative stress, immune dysfunction and increased mortality[@B1]-[@B7]. Accordingly, this issue prompted the management of blood glucose levels to become a crucial prevention and intervention means for critically ill patients[@B8]. Aiming for normoglycemia (blood glucose concentration of 80-110 mg/dL), also known as intensive glucose control, was demonstrated to be beneficial for the outcomes of patients admitted to the surgical ICU, as reported by a landmark single-center randomized controlled trial (RCT) conducted by Greet Van den Berghe and her colleagues in 2001[@B9], [@B10]. Subsequently, intensive blood glucose control was brought to the forefront and verified in several large RCTs among a variety of ICU categories [@B11]-[@B14]. Nevertheless, these RCTs all failed to replicate the mortality benefit of underlying intensive blood glucose control for patients in the ICU, and the largest "Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation" (NICE-SUGAR) trial even reported its potential detrimental effects [@B12].

All RCTs consistently concluded that intensive glucose control gave rise to an increased occurrence of hypoglycemia. Observational and prospective studies suggested that moderate and severe hypoglycemia (concentrations of blood glucose \<70 mg/dL and 40mg/dL, respectively) may be independently associated with increased mortality[@B15]-[@B18]. Although there is a lack of direct and strong evidence demonstrating that hypoglycemia deteriorates the patient\'s prognosis, hypoglycemia might cause long-term impairment of neurocognition, which was also difficult to evaluate[@B19]-[@B22].

The "Standards of Medical Care in Diabetes" recently developed by the American Diabetes Association (ADA) recommend the range of 140-180 mg/dL as a target level of blood glucose for the majority of critically ill patients[@B23]. In addition, the recommendation from the Surviving Sepsis Campaign showed that blood glucose level ≤180 mg/dL should be targeted in the management of blood glucose[@B24]. Clearly, the international consensus shows that intensive glucose control is not recommended for patients admitted to the ICU. However, high-quality evidence is far from adequate. In recent years, many well-designed systematic reviews and meta-analyses have been published and noted around this issue[@B25]-[@B30], including two network meta-analyses[@B28], [@B29]. The divergence of the included studies may be due to a disparate search strategy and inclusion criteria. Additionally, the Grading of Recommendations Assessment, Development and Evaluation (GRADE), which is used to evaluate the quality of evidence, was not used in many previous meta-analyses.

Consequently, our objective is to perform a comprehensive and updated systematic review and meta-analysis to explore the risks and benefits of intensive glucose control compared with usual care for patients in the ICU. We also aim to provide strong evidence of the optimal blood glucose targets for critically ill patients. Moreover, sepsis remains a serious issue in the ICU and constantly leads to poor clinical outcomes and death[@B31]. Due to the unique pathophysiological features, septic patients suffered more often from hyperglycemia[@B32], [@B33]. Likewise, Neurocritical care patients are a unique subset, and they are particularly sensitive to both hyperglycemia and hypoglycemia, which may induce free radical formation, oxidative injury and trigger apoptotic pathways, thereby impairing central nervous system and worsening clinical outcomes[@B34], [@B35]. In addition, the strategies for glucose control are reportedly different in patients with diabetes mellitus due to aberrant metabolism of blood glucose, indicating a cautious yet specific management strategy for critically ill patients with diabetes. Prospective and retrospective trials found that the beneficial effects of treating hyperglycemia may not be the same in critically ill patients with diabetes mellitus, and lowering blood glucose excessively in this population may be detrimental[@B18], [@B36]-[@B40]. Given that, we plan to conduct subgroup analyses with four subsets: different ICU admission categories (medical ICU, surgical ICU and medical-surgical mixed ICU), critically ill patients complicated with sepsis or septic shock, critically ill patients with diabetes mellitus as well as neurocritical care patients.

Methods
=======

Search strategy
---------------

We identified all studies relevant to our research by systematically searching MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. We conceived a strategy that comprised the following combination of exploded medical subject heading (MeSH) terms and text words: \"blood glucose\", \"insulin\", "glycemic control", "intensive care unit", "critical care", "critical illness", \"postoperative care\", \"sepsis\", "myocardial infarction", "cardiovascular surgical procedures", "stroke", \"wounds and injury\", and "septic shock". Additionally, we used highly specific search filters furnished by the Health Information Research Unit (HIRU) at McMaster University. We performed similar searches using the EMBASE and CENTRAL databases to comprehensively incorporate all related RCTs that compared intensive versus conventional glucose control in the clinical settings of critically ill patients. Additionally, we manually screened abstracts from conferences and valid data from other published systematic reviews and meta-analyses. Our search was conducted up to September 1, 2018, and included RCTs without any language limitations.

Study selection
---------------

### Inclusion criteria

We incorporated studies in accordance with the following criteria: (1) all recruited patients were adults (age\>18 years) with hyperglycemia; (2) all studies were incorporated that reported patients with critical illnesses (e.g., ICU); (3) the enrolled studies compared a minimum of two arms of intensive glucose control and regular glucose control in which variability in the glucose goal could be established; (4) the intervention of glucose control was limited to insulin infusion.

### Exclusion criteria

1\. Unpublished trials were excluded; 2. We excluded studies in which glucose control was not implemented by means of insulin administration or glucose-insulin-potassium infusions (GKIs); and 3. Trials were excluded if we could not obtain sufficient information on the results and intervention methods from the authors.

Two authors (RQY and CR) screened the titles and abstracts of studies independently. In the case of the potentially eligible trials without sufficiently validated details, the full-text was required for further consideration. Disagreements between the two reviewers were addressed by discussion. If a consensus could not be reached, the corresponding authors (ZFX and YMY) dealt with the disagreements.

Data extraction and quality evaluation
--------------------------------------

Two reviewers independently accessed and extracted data from all included RCTs. First author, the number of participants, year of publication, patient baseline characteristics, setting, clinical outcomes and target glucose concentration of each trial were abstracted and recorded by using a predesigned, standardized form. In addition, severe hypoglycemic episodes referring to the status when blood glucose concentrations fell below 40 mg/dL were also recorded and analyzed. Missing data were obtained by means of contacting authors directly.

We performed assessments of risk of bias by using the Cochrane Collaboration tool. The randomization sequence, allocation concealment, blinding of personnel and participants, risk of incomplete outcome data, selective reporting bias and other sources of bias were evaluated by two authors. A score of \'low\', \'high\' or \'unclear\' bias was attributed to each option, and then each trial was rated as having a low, moderate or high risk of bias accordingly.

The quality of evidence was assessed in line with the GRADE tools, which were processed with GRADE Pro software 3.6 (McMaster University 2014, Hamilton, Canada).

Outcome measurements
--------------------

### Primary outcomes

We chose all-cause mortality as the primary outcome because it was the most valid criterion for the detection of which protocol of glucose control was superior. In accordance with Wiener\'s meta-analysis, we preferentially used data of mortality occurring during the hospital stay or within 30 days following admission[@B27].

### Secondary outcomes

The secondary outcomes included severe hypoglycemia, need for renal replacement therapy (RRT), infection resulting in sepsis, ICU mortality, 90-day mortality, 180-day mortality, hospital and ICU length of stay. The universal definition of severe hypoglycemia was a blood glucose level below 40 mg/dL. Hypoglycemia was a commonly complicated yet extremely dangerous outcome which might cause irreversible brain injury, especially for patients who underwent insulin infusion. Although precise criteria were not provided by the included RCTs, the proportion of patients who needed RRT still represented a crucial endpoint for sepsis or septic shock patients during insulin therapy. Infection and sepsis were also selected because of their predictive value of prognosis. In addition, infection rates were presented with contradictions among different trials. The incidence of sepsis was in accordance in the RCTs.

Subgroup analyses
-----------------

### ICU setting

Given that the prognosis of critical patients may differ from disparate ICU admission, we stratified RCTs into three tiers: medical ICU (containing neurologic patients and general medical patients), surgical ICU (including patients who had undergone cardiac surgery, neurocritical surgery, abdominal surgery and general surgery) and mixed ICU (medical-surgical ICU).

### Septic patients

Insulin infusion in various clinical settings may be different due to its particular pathophysiologic characteristics. Therefore, we performed subgroup analyses by categorizing trials into septic ICU settings to address the discrepancy of insulin therapy among patients diagnosed with sepsis or septic shock.

### Neurocritical care patients

Hyperglycemia is detrimental to central nervous system in many dimensions, which reportedly worsen the prognosis of neurocritical care patients[@B19], [@B34]. Given that, we aimed to perform a subgroup analysis and compared patients-centered outcomes between two strategies regarding to patients with associated conditions, including traumatic brain injury (TBI), aneurysmal subarachnoid hemorrhage (SAH), spontaneous intracerebral hemorrhage (ICH) and ischemic stroke.

### Diabetic patients

Unlike previously reported systematic reviews and meta-analyses in which subgroup analyses were conducted based on specific target concentrations of blood glucose under intensive control, we planned to identify whether preexisting chronic hyperglycemia may affect the goals of different glucose control. Therefore, we conducted a subgroup analysis that enrolled patients with either prediagnosed type 1 or type 2 diabetes mellitus and further compared mortality between the two arms.

Data synthesis and statistical analysis
---------------------------------------

Our study applied ReviewManager (RevMan 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) for data processing. Odds ratios (ORs) were used for analyzing dichotomous outcomes, while continuous outcomes were analyzed by mean differences. We calculated a pooled-data estimate and 95% confidence intervals (CIs) for each outcome (p value less than 0.05 indicated statistical significance). The significance of heterogeneity was evaluated by Cochran\'s I^2^ test provided by the software, in which I^2^\>25% revealed a moderate or high degree of heterogeneity, and I^2^\<25% revealed a low degree of heterogeneity; the Q test was used as well (a value below 0.10 was deemed as statistically significant). In the present work, we applied a random-effects model based on the Cochrane Collaboration recommendation in the case of meaningful heterogeneity. If no moderate or high degree of heterogeneity was present in our meta-analysis, we applied a fixed-effects model accordingly. In addition, we performed sensitivity analysis by excluding the enrolled studies one at a time from the pooled data.

We assessed the publication bias of the primary outcome by means of visually inspecting the funnel plot and conducting Begg\'s and Egger\'s tests (p value \< 0.05 considered statistically significant). If publication bias existed, the trim-and-fill computation method was applied to evaluate the impact of publication bias on the interpretation of results.

Results
=======

Literature search and study characteristics
-------------------------------------------

We identified a total of 2691 citations through the database search (735 from MEDLINE, 971 from CENTRAL and 964 from EMBASE) and other sources (8 from conference abstracts and 13 from previously published systematic reviews and meta-analyses). After screening abstracts and titles, we removed the majority of trials on account of not being RCTs, not being conducted in an-ICU setting, not being original publications and performing the wrong comparison. Subsequently, the full texts of 118 potentially eligible RCTs were scanned. We excluded 42 trials due to them reporting irrelevant outcomes rather than the predefined primary or secondary outcomes. The detailed screening procedure is provided in **Figure [1](#F1){ref-type="fig"}**. Eventually, 57 trials involving a total of 21840 patients were incorporated into our systematic review and meta-analysis, which comprised 52 full publications and 5 conference abstracts[@B9], [@B11]-[@B14], [@B41]-[@B92].

The characteristics of all enrolled studies are shown in **Table [1](#T1){ref-type="table"}**. Trials with publication years ranging from 1991 to 2018 were implemented in diverse countries and medical centers, in which the majority of RCTs were conducted in single-center settings. Sample sizes also varied. The smallest trial enrolled only 10 patients, while the largest trial enrolled 6104 participants[@B12], [@B48]. Among all included studies, 29 included fewer than 100 participants, while 7 trials enrolled more than 1000 patients. The protocols of intensive insulin therapy were diverse: blood glucose concentrations less than 99 mg/dL contributed to the strictest target of glucose control, while the moderate glucose goal was between 120 mg/dL and 160 mg/dL and was applied by Giakoumidakis and his colleagues[@B61]. Most of the trials implemented tight glucose control with a glucose goal within the range of 80 mg/dL to 120 mg/dL. This systematic review and meta-analysis covered a large number of clinical ICU settings. Sixteen trials were conducted in the medical ICU, while 18 trials recruited only surgical patients. The remaining RCTs were conducted in mixed (surgical -medical) ICU settings. Moreover, 13 trials enrolled patients diagnosed with sepsis or septic shock, and of these trials, 10 RCTs enrolled exclusively septic patients[@B11], [@B12], [@B42], [@B43], [@B51], [@B58], [@B67], [@B69], [@B76], [@B81], [@B83], [@B91], [@B92]. The baseline characteristics of all participants were the same between the two arms (intensive glucose control vs conventional glucose control). In addition, the occurrence of type I or type II diabetes mellitus ranged from 0% to 100% among the included studies.

Primary outcome: All-cause mortality
------------------------------------

Within this meta-analysis, 36 trials reported hospital mortality directly, and 21 studies provided useable data that conformed to our pre-claimed definition. By graphing a forest plot of all eligible RCTs, we found that critical ill patients undergoing intensive glucose control presented with a reduced risk of all-cause death compared to those undergoing usual care, and the difference was statistically significant (OR: 0.89; 95% CI: 0.80-1.00; *P*=0.04; I^2^=32%) (**Figure [2](#F2){ref-type="fig"}**). The test for heterogeneity indicated that the trial by Finfer S et al. was an outlier, which might have been due to its overly large sample size. The exclusion of this trial significantly diminished heterogeneity without affecting the conclusion (OR: 0.88; 95% CI: 0.79-0.98; *P*=0.02; I^2^=22%)[@B12].

As shown in**Figure [3](#F3){ref-type="fig"}** and**Table [2](#T2){ref-type="table"}**, we performed a subgroup analysis based on different ICU settings, including medical ICU, surgical ICU and mixed (medical-surgical) ICU settings. Intensive glucose control significantly reduced all-cause mortality compared with usual care in the medical ICU settings (OR: 0.75; 95% CI: 0.59-0.95; *P*=0.02; I^2^=6%) as well as the surgical ICU settings (OR: 0.83; 95% CI: 0.70-0.99; *P*=0.04; I^2^=1%). However, a contradictory result was noted in the mixed ICU settings, as evidenced by no significant difference in all-cause mortality between intensive control and conventional strategy (OR: 0.97; 95% CI: 0.84-1.11; *P*=0.65; I^2^=42%). The heterogeneity test solely identified a moderate degree of heterogeneity among patients in a mixed ICU setting, with an I^2^ value of 42%. Sensitivity analysis revealed the trial by Wang et al. as the main source of heterogeneity[@B87]. When the outlying study was removed, heterogeneity was then diminished significantly (I^2^=11%). We assumed this heterogeneity might be mainly due to the discrepancy in baseline characteristics between the two arms.

Secondary outcome: mortality in different phases, severe hypoglycemia, need for RRT, infection and sepsis, length of hospital stay and length of ICU stay
---------------------------------------------------------------------------------------------------------------------------------------------------------

Pooled effect and characteristic of each secondary endpoint were summarized in **Table [3](#T3){ref-type="table"}**. The 90-day and 180-day mortality rates were reported in 11 trials and 9 trials, respectively, and ICU mortality was analyzed in 16 trails[@B9], [@B11]-[@B14], [@B42]-[@B47], [@B49], [@B53], [@B55], [@B56], [@B59], [@B63], [@B67], [@B70], [@B71], [@B73]-[@B75], [@B77], [@B80], [@B82], [@B85], [@B88], [@B89], [@B91]. No significant difference was observed in 90-day mortality (OR: 1.04, 95% CI: 0.95-1.13, *P*=0.39; I^2^=3%), 180-day mortality (OR: 0.99, 95% CI: 0.81-1.20, *P*=0.89; I^2^=0%) and ICU mortality (OR: 0.95, 95% CI: 0.85-1.06, *P*=0.36; I^2^=19%) between critically ill patients undergoing intensive glucose control and those receiving usual care (**Supplemental [Figure S1](#SM0){ref-type="supplementary-material"}-S3**).

Severe hypoglycemia episodes were reported in 32 trials [@B9], [@B11]-[@B14], [@B42]-[@B44], [@B46], [@B48], [@B49], [@B51], [@B53], [@B55], [@B56], [@B58], [@B61], [@B63], [@B66]-[@B68], [@B71], [@B72], [@B75], [@B77], [@B79], [@B80], [@B82], [@B84], [@B86], [@B87], [@B89]. Patients in 2 trials did not develop severe hypoglycemia in any arms[@B61], [@B79]. The pooled data are presented in**Figure [4](#F4){ref-type="fig"}**, which revealed a significantly increased risk of severe hypoglycemia in the intensive glucose control group (OR: 5.63, 95% CI: 4.02-7.87 *P*\<0.00001; I^2^=67%). To address the high degree of heterogeneity, we identified a study implemented by Kalfon et al. as the major source of heterogeneity by conducting a sensitivity analysis[@B13]. In fact, the I^2^ was reduced to 47% after removing this trial. Additionally, we performed a subgroup analysis by stratifying ICU settings, which consistently resulted in an increased risk of hypoglycemia (**Supplemental [Figure S4](#SM0){ref-type="supplementary-material"}**). Trials that were conducted in medical ICU did not reveal evident heterogeneity, while both the surgical and mixed ICU subgroup showed a high degree of heterogeneity (I^2^=59%, I^2^=75%). By performing a meta-regression analysis, we found no association between the incidence of severe hypoglycemia and several potential variables, including publication year (*P*=0.289), patient admission category (*P*=0.116 and*P*=0.637), age (*P*=0.942), proportion of diabetic patients (*P*=0.088), and sample size (*P*=0.520) (**Supplemental [Figure S5](#SM0){ref-type="supplementary-material"}**). Likewise, we could not identify the outlying study in the sensitivity analysis.

The proportion of patients who needed RRT was reported in 16 trials[@B11], [@B12], [@B43], [@B44], [@B51]-[@B53], [@B55]-[@B57], [@B59], [@B60], [@B66], [@B74], [@B75], [@B91]. The pooled data did not show an increased risk of RRT caused by intensive glucose control (OR: 1.07, 95% CI: 0.95-1.20, *P*=0.29; I^2^=0%) (**Supplemental [Figure S6](#SM0){ref-type="supplementary-material"}**).

Rates of infection were documented in 19 trials[@B13], [@B42], [@B43], [@B45]-[@B47], [@B50], [@B52], [@B55]-[@B57], [@B59], [@B63], [@B65], [@B66], [@B75], [@B88], [@B89], [@B92]. As presented in **Supplemental [Figure S7](#SM0){ref-type="supplementary-material"},** we found a significantly decreased risk of infection associated with employing intensive glucose control when compared with usual care (OR: 0.65, 95% CI: 0.51-0.82, *P*=0.0002; I^2^=47%). This finding was the same for the acquired sepsis rate, as reported by 12 trials[@B9], [@B43]-[@B46], [@B50], [@B52], [@B53], [@B59], [@B74], [@B88], [@B89]. The intensive control protocol was correlated with a significant reduction in acquired sepsis (OR: 0.80, 95% CI: 0.65-0.99, *P*=0.04; I^2^=0%) (**Supplemental [Figure S8](#SM0){ref-type="supplementary-material"}**).

A total of 27 trials reported evidence of length of ICU stay[@B9], [@B11], [@B12], [@B42]-[@B44], [@B46], [@B52], [@B53], [@B55], [@B56], [@B59]-[@B61], [@B63], [@B65]-[@B67], [@B69], [@B72], [@B75], [@B80], [@B85], [@B87]-[@B89], [@B92]. It should be noted that 16 trials provided the data as median and interquartile range[@B9], [@B11], [@B12], [@B42], [@B46], [@B55], [@B56], [@B63], [@B65]-[@B67], [@B75], [@B80], [@B89], [@B92]. By pooling data from the remaining 12 trials, we demonstrated that intensive glucose control significantly shortened the length of ICU stay in comparison with usual care (MD: -0.70, 95% CI: -1.21\--0.19, *P*=0.007, I^2^=70%)[@B43], [@B44], [@B52], [@B53], [@B59]-[@B61], [@B69], [@B72], [@B85], [@B87], [@B88] (**Supplemental [Figure S9](#SM0){ref-type="supplementary-material"}**). We stratified all included trials by ICU setting and conducted a subgroup analysis. Heterogeneity was resolved in each subset of trials. (**Supplemental [Figure S10](#SM0){ref-type="supplementary-material"}**). Consistent results were detected in both the medical ICU and mixed ICU settings, while no significant association was identified in the length of ICU stay between intensive glucose control and usual care groups in the surgical ICU setting.

Length of hospital stay was documented in 15 trials, but only 8 studies were eligible for analysis[@B12], [@B42]-[@B44], [@B50], [@B52], [@B60], [@B61], [@B63], [@B66], [@B72], [@B75], [@B78], [@B80], [@B84]. A pooled-estimate revealed that reduction in the length of hospital stay was associated with intensive glucose control when compared with usual care (MD: -1.29, 95% CI: -2.56\--0.01, *P*=0.05, I^2^=61%)[@B43], [@B44], [@B52], [@B60], [@B61], [@B72], [@B78], [@B84] (**Supplemental [Figure S11](#SM0){ref-type="supplementary-material"}**). By performing sensitivity analysis, we found that the trial conducted by Okabayashi and his colleagues was the main source of heterogeneity[@B78]. The exclusion of outliers significantly lowered the heterogeneity (I^2^=41%) while simultaneously changing the finding to a nonsignificant reduction in the length of hospital stay (*P*=0.16). Therefore, intensive glucose control showed no impact on the length of hospital stay based on current evidences.

Subgroup analysis
-----------------

### ICU settings

Stratifying trials according to different ICU settings was conducted for several outcomes, including all-cause mortality, severe hypoglycemia and length of ICU stay. The purpose of this subgroup analysis was to verify the consistency of major findings among distinct populations and simultaneously address a high degree of heterogeneity. The detailed information of each subgroup analysis was presented in **Table [2](#T2){ref-type="table"}**.

### Septic patients

We performed a subgroup analysis in patients diagnosed with sepsis or septic shock, and a total of 13 trials containing 3107 eligible patients were enrolled accordingly[@B11], [@B12], [@B42], [@B43], [@B51], [@B58], [@B67], [@B69], [@B76], [@B81], [@B83], [@B91], [@B92]. As shown in**Figure [5](#F5){ref-type="fig"}**, we found no significant relationship between all-cause mortality and the intensive glucose control strategy (OR: 0.96, 95% CI: 0.73-1.25, *P*=0.74; I^2^=40%). The exclusion of the outlying trial conducted by Jin et al. radically eliminated heterogeneity (I^2^=0%), and the outcome remained unchanged[@B69].

### Neurocritical care patients

By enrolling 19 trials with 2800 neurocritical care patients[@B9], [@B43], [@B45]-[@B47], [@B49], [@B53], [@B55], [@B62], [@B63], [@B70], [@B71], [@B82], [@B84], [@B86], [@B88]-[@B90], [@B92], we haven\'t observed statistically significance in all-cause mortality between intensive glucose control strategy and usual care (OR: 0.91, 95% CI: 0.75-1.10, *P*=0.32; I^2^=0%) (**Figure [6](#F6){ref-type="fig"}**).

### Diabetic patients

We included 8 studies that included 2217 patients with previously diagnosed diabetes [@B9], [@B12], [@B14], [@B43],[@B50],[@B54],[@B56],[@B72]. There were no significant differences in all-cause mortality between the two glucose control methods (OR: 1.12, 95% CI: 0.91-1.37, *P*=0.28, I^2^=0%) (**Figure [7](#F7){ref-type="fig"}**).

Quality of evidence and risk of bias
------------------------------------

We listed the summary of findings for the outcomes of interest and the levels of evidence in **Table [3](#T3){ref-type="table"}** and**Supplemental [Table S1](#SM0){ref-type="supplementary-material"}**. The primary endpoint was ranked as outcome with low quality of evidence due to inconsistency across enrolled studies and potential publication bias. The qualities of majority of secondary outcome data, including mortality associated with different phases, severe hypoglycemia infection and sepsis were all ranked as moderate. However, RRT as well as the lengths of hospital and ICU stays displayed low quality.

Most of the RCTs met the randomization requirements and used rational distribution methods. In each of the included trials, it was particularly challenging to blind the attending physicians and nurses to the outcome assessment based on the nature of the intervention, which inevitably resulted in a high risk of performance bias. Five trials that were reported in conference abstracts had high percentages of unclear risks (**Supplemental [Figure S12](#SM0){ref-type="supplementary-material"}**).

Publication bias
----------------

We constructed a funnel plot to assess the possible publication bias of all-cause mortality and severe hypoglycemia (**Supplemental [Figure S13](#SM0){ref-type="supplementary-material"}-S14**). By visually inspecting the funnel plot, we found no evidence of publication bias for severe hypoglycemia but an evident asymmetry for the primary outcome of all-cause mortality. Furthermore, we used Begg\'s test and Egger\'s test to evaluate the funnel plots of both outcomes, which showed no statistically significant evidence of publication bias for severe hypoglycemia (Egger\'s test: =0.28; Begg\'s test: p=0.2), while a significant publication bias was detected for all-cause mortality (Egger\'s test: p=0.03; Begg\'s test: p=0.99) (**Supplemental [Figure S13](#SM0){ref-type="supplementary-material"}-S14**). By further performing trim-and-fill computation, the pooled effect remained unchanged. Therefore, we demonstrated that the primary outcome was not impacted by the effect of publication bias.

Discussion
==========

In our systematic review and meta-analysis of RCTs comparing intensive glucose control with usual care in critically ill patients, we found that intensive glucose control might potentially reduce the risk of all-cause death, infection and acquired sepsis. However, the all-cause mortality benefits were limited to the medical and surgical ICU settings, while no significant difference was identified for all-cause mortality between intensive glucose control and usual care in a mixed medical-surgical ICU setting. In addition, we did not observe any beneficial effects of intensive glucose control on mortality in other phases of follow-up, including 90-day, 180-day and ICU-stay follow-ups. We also found no correlation between intensive glucose control and increased risk of RRT requirement. On the other hand, we found an approximately 6-fold increase in the occurrence of severe hypoglycemia in critically ill patients who received intensive glucose control compared with the patients who received usual care. Although there was high heterogeneity within the analysis of this outcome, the risk of severe hypoglycemia was consistently increased in association with any type of ICU admission in the intensive control arm, which indicated strong relevance. Moreover, a significant shorter length of ICU stay was observed in patients treated with intensive glucose control when compared with those treated with usual care, but the findings solely applied to the medical ICU and mixed ICU settings but not in surgical ICU setting. Likewise, we found no significant reduction in the length of hospital stay. Altogether, we found that intensive glucose control benefited critically ill patients in many dimensions. Although intensive glucose control was associated with a higher risk of hypoglycemia, we had no reason to suspect that the risk of hypoglycemia offset the benefits of intensive glucose control in reducing mortality, infection rate and duration of ICU stay.

Relation to prior works and interpretations
-------------------------------------------

Strikingly, our meta-analysis drew discrepant conclusions when compared with the conclusions of previously published meta-analyses [@B25]-[@B29]. A landmark meta-analysis by Wiener and his colleagues concluded that tight glucose control was not associated with a significant reduction in hospital mortality in the wide spectrum of critically ill patients[@B27]. While the updated study by Griesdale et al suggested that intensive glucose control might benefit patients in the surgical ICU, they failed to demonstrate any mortality benefit among medical ICU patients[@B12], [@B25]. In addition, two recently published network meta-analyses consistently revealed no significant differences in the risk of mortality among four blood glucose ranges for critically ill patients[@B28], [@B29]. However, two other meta-analyses reported a reduction in the risk of acquired sepsis in the surgical ICU setting[@B26], [@B27]. For the first time, the present work reported a significant reduction in ICU stay in patients under intensive glucose control, which has not been previously chosen as a secondary outcome. The significantly increased risk of severe hypoglycemia in the intensive glucose control group was in line with the findings of prior meta-analyses[@B25]-[@B29].

The first systematic review and meta-analysis that specifically concentrated on glucose management among septic patients was conducted by Song and his colleagues[@B30]. Our study updated Song\'s work by adding two additional trials [@B76], [@B81]. Indeed, septic patients were more susceptible to glucose variability, which was independently associated with higher mortality rates than hyperglycemia [@B33], [@B93]-[@B96]. Therefore, our finding was in line with the latest version of the guidelines, which recommended a moderate glucose goal (blood glucose concentration\<180 mg/ dL)[@B24].

We further performed a subgroup analysis of critically ill patients who were pre-diagnosed with diabetes, and found no significant difference between the two arms. We assumed that the analysis might need to include more RCTs, in which chronic hyperglycemia status (diabetes mellitus) should be taken into account [@B10], [@B21]. Likewise, we conducted a meta-regression to determine whether the prevalence of diabetes at baseline was related to the risk of mortality and found a negative association, suggesting that a history of diabetes was not an independent risk factor for all-cause mortality.

As noted, hyperglycemia leads to several adverse effects on fluid balance, immune function and inflammation[@B97], [@B98]. The present work revealed a significantly increased risk of severe hypoglycemia in patients treated with intensive glucose control, which was consistent with previously published meta-analyses and several prospective, randomized controlled trials[@B12], [@B13], [@B25], [@B27]-[@B29], [@B42]. As documented previously, hypoglycemia was associated with an increased risk of mortality and might act as an independent hazard[@B9], [@B15]-[@B18], [@B42]. However, the direct relationship between hypoglycemia and worse prognosis in the short and long-term follow-up remained unclear[@B10], [@B20], [@B22], as neurologic damage caused by hypoglycemia was only explored in animal models[@B99]-[@B101].

We initially reported a significant reduction in the duration of ICU stay when patients underwent intensive glucose control. Nevertheless, the result of subgroup analysis of patients admitted to the medical ICU must be interpreted prudently because only two studies were enrolled with only 159 patients in the intensive control arm and 175 patients in the usual care arm [@B69], [@B88].

Limitations
-----------

Although the present meta-analysis of 57 randomized controlled trials was the most comprehensive meta-analysis, several limitations were inevitable during the implementation of this study. First, we found a significant publication bias for the primary outcome by using Begg\'s and Egger\'s test. Although we further confirmed that our conclusions could not be reversed by publication bias via conducting trim-and-fill tests, the potential effect of publication bias could not be entirely ruled out due to several limitations of this method. In addition, the test of heterogeneity revealed a moderate degree of heterogeneity, which was resolved by means of sensitivity analysis. However, many factors, such as feeding regimen, glucose control methods and the use of monitoring devices, still need to be fully elucidated in regard to whether they contributed to the heterogeneity among the included studies. Second, our search strategy seemed to be loose and covered almost all relevant trials addressing the usage of intensive glucose control among critically ill patients, which have been incorporated in previously published systematic reviews and meta-analyses [@B25]-[@B30], [@B35]. Given that, we screened our included RCTs cautiously and carefully considered eligibility for every enrolled trials. In addition, we took many trials with small sample sizes into account, which may influence the pooled data estimates. Third, we did not stratify the range of target blood glucose into subgroups because almost all trials presented with the same intensive glucose control protocol, in which the glucose goal was within the range of 80 mg/dL to 120 mg/dL. Besides, it should be noted that a few studies did exist, in which disparate intensive insulin strategies were implemented, and might potential introduce bias and impair the robustness of the conclusions. Fourth, practical difficulties should be noted. When each arm of trials failed to attain the glucose target, it might introduce bias. Finally, as insufficient data of secondary endpoints was provided by enrolled trials, we were unable to assess other sources of bias for several secondary outcomes. Thus, more advanced glucose monitoring devices such as artificial pancreas should urgently be equipped for better outcomes [@B28].

Conclusions
===========

The current systematic review and meta-analysis demonstrated that an intensive glucose control strategy among critically ill patients was potentially associated with a reduced risk of all-cause death in comparison to a regular glucose control strategy. Moreover, our results revealed that ICU patients who underwent intensive glucose control did not increase the risk of developing infection and sepsis during hospitalization and that their ICU length of stay was relatively shorter than that of those who received usual care. Consistent with previous studies, we found that the risk of severe hypoglycemia was significantly elevated among patients with intensive glucose control. Our results might indicate the beneficial role of an intensive glucose control strategy in many dimensions, which challenged the current recommendation of glucose control strategy in critically ill patients. We believe that further clinical trials are required to test our findings.
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###### 

Characteristics of all eligible randomized control trials comparing intensive glucose control to usual care among critically ill patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                  Year   No. of sites   No. of patients   ICU Setting    Diabetic\   Age\      Intensive glucose control         Usual care   Follow- up                              
                                                                                 (%)         (years)                                                                                          
  ----------------------- ------ -------------- ----------------- -------------- ----------- --------- --------------------------- ----- ------------ --------------------------------- ----- ---------------
  Annane [@B42]           2010   8              509               Mixed ICU      N/A         64        80-110                      124                180-200                           150   6 months

  Arabi [@B43]            2008   1              523               Mixed ICU      40%         52.4      80-110                      115                180-200                           171   Hospital stay

  Arabi [@B44]            2011   1              240               Mixed ICU      40%         51.1      80-110                      112                180-200                           155   6 months

  Bilotta [@B47]          2007   1              78                Surgical ICU   10%         52.5      80-120                      93                 -220                              147   6 months

  Bilotta [@B45]          2008   1              97                Surgical ICU   12%         52.5      80-120                      92                 -220                              147   6 months

  Bilotta [@B46]          2009   1              483               Surgical ICU   10%         57.1      80-110                      92                 -215                              143   6 months

  Bland [@B48]            2005   1              10                Medical ICU    40%         56.7      80-110                      105                180-200                           177   28 days

  Brunkhorst [@B11]       2008   18             537               Mixed ICU      30%         64.6      80-110                      112                180-200                           151   90 days

  Bruno [@B49]            2008   5              46                Medical ICU    91%         59.1      90-130                      133                -200                              190   90 days

  Cao [@B50]              2011   1              179               Surgical ICU   100%        58.8      80-110                      99                 180-198                           178   28 days

  Cappi [@B51]            2012   1              63                Mixed ICU      24%         53        80-110                      99                 140-180                           155   Hospital stay

  Chan [@B52]             2009   1              109               Surgical ICU   29%         57.5      80-130                      127                160-200                           168   30 days

  Coester [@B53]          2010   1              88                Surgical ICU   1%          38.5      80-110                      123                -180                              145   6 months

  Davies [@B54]           1991   4              69                Medical ICU    100%        62        72-144                      185                -180                              193   Hospital stay

  De Azevedo [@B55]       2010   2              337               Mixed ICU      31%         56.2      80-120                      134                -180                              144   ICU stay

  De La Rosa [@B56]       2008   1              504               Mixed ICU      12%         46.6      80-110                      117                180-200                           149   Hospital stay

  Desai [@B57]            2012   1              189               Surgical ICU   43%         62.7      90-120                      N/A                121-180                           N/A   30 days

  Dong [@B58]             2009   1              27                Medical ICU    0%          44        74-110                      108                112-150                           148   Hospital stay

  Farah [@B59]            2007   1              89                Mixed ICU      60%         73.1      110-140                     142                140-200                           174   28 days

  Fernandez^\#^ [@B81]    2005   1              20                Medical ICU    85%         71.9      80-110                      120                180-200                           205   Hospital stay

  Finfer [@B12]           2009   42             6104              Mixed ICU      20%         60.2      81-108                      118                -180                              145   90 days

  Gandhi [@B60]           2007   1              371               Surgical ICU   20%         63        80-100                      113                -200                              157   Hospital stay

  Giakoumidakis [@B61]    2013   1              212               Surgical ICU   29%         65.9      120-160                     154                161-200                           174   Hospital stay

  Gray [@B62]             2007   21             933               Surgical ICU   16%         75.2      72-126                      113                -306                              122   20 days

  Green [@B63]            2010   1              81                Mixed ICU      N/A         51        80-110                      112                -150                              143   90 days

  Grey [@B64]             2004   1              61                Surgical ICU   12%         55.6      80-120                      125                180-220                           179   Hospital stay

  He [@B65]               2007   1              188               Mixed ICU      18%         65.5      80-110                      108                180-200                           180   Hospital stay

  Henderson [@B66]        2009   1              67                Mixed ICU      9%          56.5      90-126                      113                162-198                           151   28 days

  Jin^\#^ [@B69]          2009   14             356               Medical ICU    N/A         65.7      80-110                      99                 180-200                           189   28 days

  Johnston [@B70]         2009   2              74                Medical ICU    60%         68.3      70-110                      112                -200                              151   90 days

  Kalfon [@B13]           2014   34             2684              Mixed ICU      20%         61.5      80-110                      115                -180                              126   90 days

  Kia^\#^ [@B73]          2005   1              265               Surgical ICU   26%         68.2      75-115                      109                180-200                           144   90 days

  Kreisel [@B71]          2009   1              40                Medical ICU    33%         71.6      80-110                      117                -200                              144   120 days

  Iapichino [@B67]        2008   3              72                Mixed ICU      17%         62.3      80-110                      110                180-200                           163   90 days

  Lazar [@B72]            2011   1              82                Surgical ICU   100%        64        90-120                      103                120-180                           135   30 days

  Mackenzie^\#^ [@B68]    2005   2              240               Mixed ICU      83%         64.5      72-108                      126                180-198                           151   Hospital stay

  Mahmoodpoor [@B74]      2011   1              60                Surgical ICU   15%         52.8      80-120                      109                -200                              141   ICU stay

  McMullin [@B75]         2007   1              20                Mixed ICU      55%         68.8      90-126                      128                144-180                           169   Hospital stay

  Meng [@B89]             2009   1              240               Surgical ICU   10%         46        80-110                      N/A                180-200                           N/A   6 months

  Miranda [@B76]          2013   1              27                Medical ICU    N/A         53.8      80-110                      N/A                180-220                           N/A   72 hours

  Mitchell [@B77]         2006   1              70                Mixed ICU      14%         65.8      80-110                      97                 180-200                           142   Hospital stay

  Okabayashi [@B78]       2014   1              502               Surgical ICU   24%         66.5      80-110                      106                140-180                           155   Hospital stay

  Oksanen [@B79]          2007   2              90                Medical ICU    79%         64        72-108                      90                 108-144                           115   30 days

  Preiser [@B80]          2009   21             1078              Mixed ICU      19%         64.6      80-110                      117                140-180                           144   Hospital stay

  Rosso [@B82]            2012   1              180               Medical ICU    13%         73.3      -99                         103                -144                              117   90 days

  Savioli [@B83]          2009   3              90                Mixed ICU      13%         61        80-110                      112                180-200                           159   28 days

  Staszewski [@B84]       2011   1              50                Medical ICU    0%          77.1      81-126                      108                180-                              122   30 days

  Stecher^\#^ [@B41]      2006   1              117               Surgical ICU   13%         52.6      80-110                      N/A                140-180                           N/A   N/A

  Taslimi [@B85]          2009   1              129               Mixed ICU      53%         55.5      80-110                      N/A                125-225                           N/A   ICU stay

  Van den Berghe [@B9]    2001   1              1548              Surgical ICU   13%         62.8      80-110                      103                180-200                           153   Hospital stay

  Van den Berghe [@B14]   2006   1              1200              Medical ICU    17%         63.5      80-110                      111                180-200                           153   90 days

  Walters [@B86]          2006   1              25                Medical ICU    52%         74.9      90-144                      122                -270                              135   30 days

  Wang [@B87]             2006   1              116               Mixed ICU      11%         65.1      80-110                      99                 180-200                           185   Hospital stay

  Wang [@B88]             2017   1              88                Medical ICU    19%         46.7      80-110                      N/A                180-200                           N/A   6 months

  Yang [@B90]             2009   1              110               Medical ICU    N/A         59.7      80-150                      160                Treated withtwice daily insulin   229   N/A

  Yu [@B91]               2005   1              55                Mixed ICU      N/A         46        80-110                      103                180-200                           198   Hospital stay

  Zhang [@B92]            2008   1              338               Surgical ICU   28%         60.9      80-110                      110                130-150                           139   Hospital stay
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ICU, intensive care unit; N/A, not available from manuscript or authors.

\#: Abstract only.

###### 

Subgroup analyses on all-cause mortality

  Subgroup                      No. of studies                    No. of patients   OR (95% CI)   I^2^               *P* value   
  ----------------------------- --------------------------------- ----------------- ------------- ------------------ ----------- ------
  **Admission category**                                                                                                         
                                Medical ICU                       16                2295          0.75 (0.59-0.95)   6%          0.02
                                Surgical ICU                      18                5605          0.83 (0.70-0.99)   1%          0.04
                                Mixed ICU                         23                13940         0.97 (0.84-1.11)   42%         0.65
  **Sepsis and septic shock**                                                                                                    
                                Septic patients                   13                3107          0.96 (0.73-1.25)   40%         0.74
                                Non-septic patients               47                18753         0.89 (0.79-1.01)   33%         0.07
  **Neurocritical illness**                                                                                                      
                                Neurocritical care patients       19                2800          0.91 (0.75-1.10)   0%          0.32
                                Non-neurocritical care patients   42                19050         0.88 (0.77-1.01)   45%         0.08
  **Diabetes mellitus**                                                                                                          
                                Diabetic patients                 8                 2217          1.12 (0.91-1.37)   0%          0.28
                                Non-diabetic patients             54                19621         0.89 (0.79-1.00)   32%         0.05

Abbreviations: ICU, intensive care unit; OR, odds ratio; CI, confidence interval.

###### 

Summary of primary and secondary outcomes

  Outcome                   No. of studies            OR (95%CI)   MD (95%CI)         I^2^                   *P* value   Quality of evidence^a^   
  ------------------------- ------------------------- ------------ ------------------ ---------------------- ----------- ------------------------ ---------------------------------------
  **Primary endpoint**                                                                                                                            
                            All-cause mortality       57           0.89 (0.80-1.00)                          32%         0.04                     Low (Inconsistency, Publication bias)
  **Secondary endpoints**                                                                                                                         
                            90-day mortality          11           1.04 (0.95-1.13)                          3%          0.39                     Moderate (Inconsistency)
                            180-day mortality         9            0.99 (0.81-1.20)                          0%          0.89                     Moderate (Inconsistency)
                            ICU mortality             16           0.95 (0.85-1.06)                          19%         0.36                     Moderate (Inconsistency)
                            Severe hypoglycemia       32           5.63 (4.02-7.87)                          67%         \<0.0001                 Moderate (Risk of bias)
                            Need for RRT              16           1.07 (0.95-1.20)                          0%          0.29                     Low (Indirectness, Imprecision)
                            Infection                 19           0.65 (0.51-0.82)                          47%         0.0002                   Moderate (Imprecision)
                            Sepsis                    12           0.80 (0.65-0.99)                          0%          0.04                     Moderate (Imprecision)
                            ICU length of stay        12                              -0.70 (-1.21\--0.19)   70%         0.007                    Low (Inconsistency, Risk of bias)
                            Hospital length of stay   8                               -1.29 (-2.56\--0.01)   61%         0.05                     Low (Inconsistency, Risk of bias)

Abbreviations: ICU, intensive care unit; OR, odds ratio; MD, mean difference; CI, confidence interval.

^a^Quality of evidence of each outcome was assessed by using GRADE method.
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